Biocytogen and Gilead Partner to Select and Develop Therapeutic Targets for the Treatment of Multiple Diseases
Shots:
- Biocytogen has signed an antibody evaluation and option agreement with Gilead Sciences for the development of various novel antibody-based therapies to treat multiple disease
- The collaboration grants Gilead, access to Biocytogen’s fully human antibody library to select the targets of interest over a 3yr. nomination period and investigate them with an option to own the selected antibodies for development across the globe
- Biocytogen will obtain payment for helping Gilead in investigating antibodies for nominated target, option exercise fees, milestones for achieving development, regulatory & sales for each selected antibody against the nominated targets along with single-digit net sales-based royalties
Ref: Biocytogen| Image: Biocytogen
Related News:- Biocytogen and Neurocrine Biosciences Sign an Antibody Evaluation and Option Agreement
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
